NasdaqGS:ILMNLife Sciences
The Bull Case For Illumina (ILMN) Could Change Following Buybacks And NovaSeq X Roadmap Reveal – Learn Why
In the months to 11 February 2026, Illumina completed a share repurchase program, buying back 9,958,000 shares, or 6.31% of its stock, for US$1.02 billion, while also unveiling an 18‑month NovaSeq X innovation roadmap that targets up to Q70 quality scores, faster runs, and higher read outputs.
This combination of capital returns and higher‑performance, more cost‑efficient sequencing could materially influence how investors assess Illumina’s productivity, competitiveness, and longer‑term...